Telik, Inc. Share Price Nasdaq
Equities
US87959M1099
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
Sales 2016 | 148K 11.82M | Sales 2017 | - | Capitalization | 14.41M 1.15B |
---|---|---|---|---|---|
Net income 2016 | -17M -1.36B | Net income 2017 | -19M -1.52B | EV / Sales 2016 | 147 x |
Net Debt 2016 | 470K 37.52M | Net Debt 2017 | 2.48M 198M | EV / Sales 2017 | - |
P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 07/07/14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 07/07/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 07/07/14 |
1st Jan change | Capi. | |
---|---|---|
+3.99% | 108B | |
+11.10% | 104B | |
+1.28% | 22.33B | |
-12.93% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.43% | 17.64B | |
+3.57% | 14.05B | |
+36.99% | 12.51B |